BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

15 articles for JL Ditta

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.EBI
Bristol-Myers Squibb Research and Development
Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents.EBI
Bristol-Myers Squibb
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI
Bristol-Myers Squibb
Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists.EBI
Bristol-Myers Squibb Research and Development
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist.EBI
Bristol-Myers Squibb
Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists.EBI
Bristol-Myers Squibb
Aminotriazine 5-HT7 antagonists.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Conformationally restricted homotryptamines. Part 6: indole-5-cycloalkyl methylamines as selective serotonin reuptake inhibitors.EBI
Bristol-Myers Squibb Research and Development
Spirocyclic compoundsBDB
Recurium Ip Holdings
In vitro effects of some drugs on human erythrocyte glutathione reductase.BDB
Ataturk University